@darvasboxtrader There is one major real problem in this process, in between many trusted sources like fufa, taau ji, chacha, mama also recommending bio-datas which creates lot of confusion. 🤪
As they all looks very attractive because you are desperate to marry 😀
$MU
FQ3 FY2026 Earnings → June 24
Guidance: Revenue $33.5B ±$750M, gross margin ~81%, non-GAAP EPS $19.15 ±$0.40.
Analyst estimates span a wide range — $33.7B to $40.9B in revenue — reflecting genuine uncertainty about AI data center investment pace.
Micron has crossed the $1 trillion market cap mark. MU stock up ~70% YTD and >350% over the past year.
At the JPM Tech Conference (May 2026), management flagged supply tightness expected well beyond 2026, with memory becoming increasingly strategic as AI shifts from human to agentic workloads.
Capex & Infrastructure
Committing >$25B in fiscal 2026 capex, including a new megafab in New York with Bechtel and large-scale U.S. manufacturing investments backed by CHIPS Act grants totaling up to $6.4B.
The thesis is intact: Memory is no longer a commodity — it’s AI critical infrastructure. The FQ3 print on June 24 is the next major catalyst. The bar is high, but so is the structural demand floor.
Not financial advice.
Volatility remains elevated, and today’s premarket strength will be tested once the market opens. Recently, we’ve seen many gap-up moves turn into unloading events as institutional investors take profits, so caution is still warranted.
$SPY is red now
@nsinghal211 I would respectfully request that anyone making performance-related claims either provide verifiable and transparent records to support them or refrain from making potentially misleading statements. Transparency helps build credibility and trust within the investing community.
@nsinghal211 Many finfluencers claim to generate substantial profits, yet very few provide verified and transparent proof of their performance. While there are some who openly share their verified P&L statements and maintain complete transparency, many others make claims w/o adequate evidence